Lehdistötiedote

Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki

Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the 58th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Helsinki, Finland, from May 14–17, 2025.

The study’s clinical findings will be shared in both oral and poster presentations by Prof. Teresa Del Moral (University of Miami, USA) and Prof. Flavia Indrio (University of Foggia, Italy), both of whom have been involved in The Connection Study.

IBT’s presentations will highlight data from IBP-9414, its investigational Live Biotherapeutic Product (LBP) designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.

ESPGHAN 2025 is a leading international forum for clinicians and researchers in pediatric gastroenterology, hepatology, and nutrition

Presentation Details

Oral Presentation
Title: Effect of IBP-9414 on Time to a Strict Definition of Sustained, Full Enteral Feeding in Very Low Birth Weight Infants: Results from The Connection Study
Presenter: Prof. Flavia Indrio
Date & Time: Thursday, May 15, 2025
Location: Messukeskus Helsinki, Expo and Convention Centre

Oral Presentation
Title: Effect of IBP-9414, a Live Biotherapeutic Product on Necrotizing Enterocolitis in Very Low Birth Weight Infants: Results from The Connection Study
Presenter: Prof. Teresa Del Moral
Date & Time: Thursday, May 15, 2025
Location: Messukeskus Helsinki, Expo and Convention Centre

Poster Presentation
Title: Effects of IBP-9414, a Live Biotherapeutic Product, on Necrotizing Enterocolitis, Full Enteral Feeding, and Mortality in Very Low Birth Weight Infants: Connection Study Results
Presenter: Prof. Teresa Del Moral
Date & Time: Friday, May 16, 2025
Location: Poster Area, ESPGHAN 2025 Congress Hall, e-Poster Station: Station 02

Poster Presentation
Title: IBP-9414, a Live Biotherapeutic Product, Reduces All-Cause Mortality in Very Low Birthweight Infants: Results from The Connection Study
Presenter: Prof. Flavia Indrio
Date & Time: Friday, May 16, 2025
Location: Poster Area, ESPGHAN 2025 Congress Hall, e-Poster Station: Station 05

Further details about the ESPGHAN 2025 Meeting can be found at www.espghancongress.org

About The Connection Study
The Connection Study is the largest randomized, double-blind, parallel-group, placebo-controlled trial to date evaluating the efficacy and safety of IBP-9414 in premature infants (birth weight 500–1500g) for the prevention of necrotizing enterocolitis (NEC) — a life-threatening gastrointestinal disease affecting neonates.

About Us
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are since September 10, 2018, listed on Nasdaq Stockholm (IBTB).

IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies. During the 12 years of drug development IBT has gained unique expertise in the field of drugs using live bacteria as active substances. This is a key competitive factor for our development programs.

IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. The drug development of IBP-9414 is currently in its final stages for this important product for premature babies.

The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections.

Through the development of these drugs, IBT can address medical needs where no sufficient treatments are available.